Medincell Joins Euronext SBF 120 Index

Medincell, a French biopharmaceutical company, has announced its inclusion in the prestigious Euronext SBF 120 index. This index comprises the 120 largest companies listed on Euronext Paris, integrating both the CAC 40 and other major players in the French economy. The inclusion will take effect on December 20, 2024, post-market closure.

CEO Christophe Douat expressed that this achievement signifies Medincell's robust performance since its IPO six years ago. By joining the SBF 120, Medincell anticipates increased visibility and attractiveness to both French and international investors. The move is expected to stimulate a higher volume of trading in the company's shares.

The SBF 120 index includes the CAC 40 and CAC Mid 60, both determined by Euronext's Scientific Council based on market capitalizations and liquidity. Medincell's addition reflects its strong market position and growth potential.